$10.58
-1.7%Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.7M | -$14.9M | -$11.8M | -$9.4M | -$7.5M | -$5.9M | -$4.7M | -$3.7M | -$3.0M | -$2.4M |
| Maintenance CapEx | -$2.9K | -$2.3K | -$1.8K | -$1.4K | -$1.1K | -$905 | -$719 | -$572 | -$454 | -$361 |
| Owner Earnings | -$18.7M | -$14.9M | -$11.8M | -$9.4M | -$7.5M | -$5.9M | -$4.7M | -$3.7M | -$3.0M | -$2.4M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$17.4M | -$12.8M | -$9.4M | -$6.9M | -$5.1M | -$3.7M | -$2.8M | -$2.0M | -$1.5M | -$1.1M |
Continue your BNTC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.